Eugia Pharma Specialities Receives USFDA Approval for Everolimus Tablets

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, has received final USFDA approval to manufacture and market Everolimus tablets in strengths of 0.25 mg to 1 mg. The drug, equivalent to Novartis's Zortress, is used to prevent organ rejection in kidney and liver transplant patients. The product, with an estimated $78 million market size, is expected to launch in Q1 FY27. This marks Eugia's 184th ANDA approval across its oncology and specialty product facilities.